Biomatlante SAS news

In this new context of fighting the spread of the Covid-19 virus, Biomatlante has adapted its organization in order to ensure the continuity of its services to support you in your activity.

Our regulatory, quality, R&D, commercial, marketing, administrative and financial services ensure the pursuit of their missions in home office.

We strive to maintain the activity of our production department in strict compliance with the health guide

Biomatlante, a world leader in synthetic bone regeneration technologies, is pleased to announce the obtention of the MDSAP^* accreditation on the new ISO 13485:2016 Certificate.

The Medical Device Single Audit Program (MDSAP) is an international program for assessing the quality management systems of medical device manufacturers who market their products in Australia, Brazil, Canada, Japan and/or the United States. With MDSAP, a single regulatory audit con